Drug Profile
Nitric oxide - Mallinckrodt
Alternative Names: Ik 7001; IK-3001; IK-7001; INOflo; INOmax; INOmax Total Care; INOMAX® Total Care package; INOtherapy; INOVENTLatest Information Update: 06 Sep 2019
Price :
$50
*
At a glance
- Originator Massachusetts General Hospital
- Developer AGA Linde Healthcare; Ikaria Holdings; Mallinckrodt plc
- Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antivirals; Diagnostic agents; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
- Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypoxic respiratory failure; Pulmonary hypertension
- Phase III Bronchopulmonary dysplasia; Pulmonary arterial hypertension
- Preclinical Transplant rejection
- Discontinued Heart failure; Reperfusion injury
Most Recent Events
- 16 Apr 2019 Registered for Pulmonary hypertension (In adults) in Australia (Inhalation)
- 12 Apr 2019 Launched for Pulmonary hypertension (In adults) in Australia (Inhalation)
- 01 Apr 2019 Preclinical trials in Transplant rejection in USA (Parenteral) before April 2019 (Mallinckrodt pipeline, April 2019)